Associations between Statin use and changes in pain, function and structural progression: A longitudinal study of persons with knee osteoarthritis

Annals of the Rheumatic Diseases

Volumn 72, Issue 2, 2013, Pages 196-203

  Riddle, Daniel L ^a   Moxley, George ^b   Dumenci, Levent ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; KNEE FUNCTION; KNEE OSTEOARTHRITIS; KNEE PAIN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX;

DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN;

EID: 84872066639     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202159     Document Type: Article

References (25)

1. Conaghan PG. The effects of statins on osteoarthritis structural progression: another glimpse of the Holy Grail? Ann Rheum Dis 2012;71:633-4.
2. Berenbaum F. The quest for the Holy Grail: a disease-modifying osteoarthritis drug. Arthritis Res Ther 2007;9 :111.
3. Saag KG. Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not? Ann Rheum Dis 2008;67 :1358-9.
4. Carbone LD, Nevitt MC, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004;50:3516-25.
5. Wildi LM, Raynauld JP, Martel-Pelletier J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011;70:982-9.
6. Clockaerts S, Van Osch GJ, Bastiaansen-Jenniskens YM, et al. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Ann Rheum Dis 2012;71:642-7.
7. Dieppe PA. Why is there such a poor correlation between radiographic joint damage and both symptoms and functional impairment in osteoarthritis? Br J Rheumatol 1989;28:242.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
9. Conaghan PG, Vanharanta H, Dieppe PA. Is progressive osteoarthritis an atheromatous vascular disease? Ann Rheum Dis 2005;64:1539-41.
10. Gkretsi V, Simopoulou T, Tsezou A. Lipid metabolism and osteoarthritis: lessons from atherosclerosis. Prog Lipid Res 2011;50:133-40.
11. Glintborg B, Poulsen HE, Dalhoff KP. The use of nationwide on-line prescription records improves the drug history in hospitalized patients. Br J Clin Pharmacol 2008;65:265-9.
12. Loo RL, Chan Q, Brown IJ, et al. A comparison of self-reported analgesic use and detection of urinary ibuprofen and acetaminophen metabolites by means of metabonomics: the INTERMAP Study. Am J Epidemiol 2012;175 :348-58.
13. Jensen MP, Turner JA, Romano JM, et al. Comparative reliability and validity of chronic pain intensity measures. Pain 1999; 83:157-62.
14. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15 :1833-40.
15. Bellamy N. Pain assessment in osteoarthritis: experience with the WOMAC osteoarthritis index. Semin Arthritis Rheum 1989;18:14-17.
16. Bellamy N. The WOMAC Knee and Hip Osteoarthritis Indices: development, validation, globalization and influence on the development of the AUSCAN Hand Osteoarthritis Indices. Clin Exp Rheumatol 2005;23:S148-53.
17. Bellamy N, Buchanan WW. A preliminary evaluation of the dimensionality and clinical importance of pain and disability in osteoarthritis of the hip and knee. Clin Rheumatol 1986;5:231-41.
18. Benichou OD, Hunter DJ, Nelson DR, et al. One-year change in radiographic joint space width in patients with unilateral joint space narrowing: data from the Osteoarthritis Initiative. Arthritis Care Res (Hoboken) 2010;62:924-31.
19. Cotofana S, Buck R, Wirth W, et al. Cartilage thickening in early radiographic human knee osteoarthritis - within-person, between-knee comparison. Arthritis Care Res (Hoboken) 2012;64:1681-90.
20. Katz JN, Chang LC, Sangha O, et al. Can comorbidity be measured by questionnaire rather than medical record review? Med Care 1996; 34:73-84.
21. Muthen LK, Muthen BO. Mplus User 's Guide. Los Angeles, CA: Muthen & Muthen, 2011.
22. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods 2002;7:147-77.
23. Bollen KA, Curran PJ. Latent curve models: a structural equation perspective. Wiley Series on probability and mathematical statistics. New York: Wiley Publishers, 2006.
24. Buettner C, Rippberger MJ, Smith JK, et al. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012; 125:176-82.
25. Kidd BL. Osteoarthritis and joint pain. Pain 2006;123:6-9.